Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 7/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | MMP1 | P03956 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294822 | 0.93 | CTSB (0.49) | CTSBKMT2ACTSLCTSSCTSK | |
| SCHEMBL6701120 | 0.93 | CTSB (0.49) | CTSBCTSLAVPR1ACTSSCTSK | |
| SCHEMBL6696901 | 0.89 | USP30 (0.42) | CTSBCTSLUSP30CTSSCTSK | |
| SCHEMBL6300636 | 0.89 | CTSL (0.41) | CTSBKMT2ACTSLUSP30AVPR1A | |
| SCHEMBL6695685 | 0.89 | CTSB (0.45) | CTSBKMT2ACTSLCTSSCTSK | |
| SCHEMBL6300222 | 0.88 | CTSL (0.39) | CTSBCTSLUSP30CTSSCTSK | |
| SCHEMBL6294793 | 0.87 | CTSB (0.45) | CTSBKMT2ACTSLCTSSCTSK | |
| SCHEMBL6698003 | 0.86 | CTSL (0.45) | CTSBKMT2ACTSLCTSSCTSK | |
| SCHEMBL6300527 | 0.86 | CTSL (0.38) | CTSBKMT2ACTSLUSP30CTSS | |
| SCHEMBL6992575 | 0.85 | USP30 (0.48) | CTSBCTSLUSP30CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958358-B2 | administering a cystatin; 4-tert-Butyl-N-[2-(4-hydroxyphenyl)-1S-(3-oxo-hexahydrocyclopenta[b]furan-3a-ylcarbamoyl)-ethyl]benzamide; bioassay for validation of efficacy ; Chagas' disease; parasiticide, trypanocide | AMURA THERAPEUTICS LIMITED (GB) | 2005-10-25 | — | — | US | disclosed |
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | CTSB 33/4885KMT2A 4063/4885CTSL 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.